SPX3,845.08+13.69 0.36%
DIA310.41+0.70 0.23%
IXIC11,361.85+39.61 0.35%

Wedbush Lifts Price Target on SpringWorks Therapeutics to $53 From $50 on Nirogacestat Estimates, Keeps Outperform Rating

MT Newswires · 06/13/2022 01:17

Please log in to view news